|
|
| Line 13: |
Line 13: |
| MeshNumber = C08.127.108 | | | MeshNumber = C08.127.108 | |
| }} | | }} |
| {{SI}} | | {{Asthma}} |
|
| |
|
| '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | | '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' |
|
| |
|
| '''Editor-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]]; Philip Marcus, M.D., M.P.H. [mailto:pmarcus192@aol.com], Division of Pulmonary Medicine | | '''Editor(s)-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; [[Philip Marcus, M.D., M.P.H.]] [mailto:pmarcus192@aol.com] |
| St. Francis Hospital-The Heart Center, Roslyn, NY
| |
|
| |
|
| ==Overview== | | ==[[Asthma overview|Overview]]== |
| '''Asthma''' is a [[chronic (medicine)|chronic]] [[illness]] involving the [[respiratory system]] in which the [[Lung|airway]] occasionally constricts, becomes [[inflammation|inflamed]], and is lined with excessive amounts of [[mucus]], often in response to one or more triggers. These episodes may be triggered by such things as exposure to an environmental stimulant (or [[allergen]]), cold air, warm air, moist air, [[exercise]] or exertion, or emotional [[stress (medicine)|stress]]. In children, the most common triggers are viral illnesses such as those that cause the [[common cold]].<!--
| |
| --><ref name=Zhao>Zhao J, Takamura M, Yamaoka A, Odajima Y, Iikura Y. Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood. ''J Pediatr Allergy Immunol''. 2002 Feb;13(1):47–50. PMID 12000498</ref> This airway narrowing causes [[symptom]]s such as [[wheezing]], [[dyspnea|shortness of breath]], chest tightness, and [[cough]]ing. The airway constriction responds to [[Bronchodilator|bronchodilators]]. Between episodes, most patients feel well but can have mild symptoms and they may remain short of breath after exercise for longer periods of time than the unaffected individual. The symptoms of asthma, which can range from mild to life threatening, can usually be controlled with a combination of [[medication|drugs]] and environmental changes.
| |
|
| |
|
| Public attention in the developed world has recently focused on asthma because of its rapidly increasing [[prevalence]], affecting up to one in four urban children.<!--
| | ==[[Asthma historical perspective|Historical Perspective]]== |
| --><ref name=Lilly>Lilly CM. Diversity of asthma: Evolving concepts of pathophysiology and lessons from genetics. ''J Allergy Clin Immunol''. 2005;115 (4 Suppl):S526-31. PMID 15806035</ref>
| |
|
| |
|
| ==History== | | ==[[Asthma pathophysiology|Pathophysiology]]== |
|
| |
|
| The word 'asthma' is derived from the Ancient Greek ''aazein'', meaning "sharp breath." The word first appears in Homer's ''Iliad'';<!--
| | ==[[Asthma epidemiology and demographics|Epidemiology and Demographics]]== |
| --><ref name=Marketos>Marketos SG, Ballas CN. Bronchial asthma in the medical literature of Greek antiquity. ''J Asthma''. 1982;19(4):263-9. PMID 6757243</ref>
| |
| [[Hippocrates]] was the first to use it in reference to the medical condition, in 450 BC. Hippocrates thought that the spasms associated with asthma were more likely to occur in tailors, anglers, and metalworkers. Six centuries later, [[Galen]] wrote much about asthma, noting that it was caused by partial or complete bronchial obstruction. In 1190 AD, Moses Maimonides, an influential medieval rabbi, philosopher, and physician, wrote a treatise on asthma, describing its prevention, diagnosis, and treatment.<!-- | |
| --><ref name=Rosner>Rosner F. Moses Maimonides' treatise on asthma. ''Thorax''. 1981;36:245–251. PMID 7025335</ref>
| |
| In the 17th century, Bernardino Ramazzini noted a connection between asthma and [[organic compound|organic]] dust. The use of [[bronchodilator]]s started in 1901, but it was not until the 1960s that the inflammatory component of asthma was recognized, and [[anti-inflammatory]] medications were added to the regimens.
| |
|
| |
|
| ==Epidemiology== | | ==[[Asthma risk factors|Risk Factors]]== |
| [[Image:asthma prevalence.png|thumb|left|350px|The [[prevalence]] of childhood asthma has increased since 1980, especially in younger children.]] | |
| More than 6% of children in the United States have been diagnosed with asthma, a 75% increase in recent decades. The rate soars to 40% among some populations of urban children.
| |
|
| |
|
| Asthma is usually diagnosed in childhood. The risk factors for asthma include:
| | ==[[Asthma natural history, complications and prognosis|Natural history, Complications and Prognosis]]== |
| *a personal or family history of asthma or [[atopy]];
| |
| *triggers (see ''[[Asthma#Pathophysiology|Pathophysiology]]'' above);
| |
| *premature birth or low birth weight;
| |
| *viral respiratory infection in early childhood;
| |
| *maternal smoking;
| |
| *being male, for asthma in prepubertal children; and
| |
| *being female, for persistence of asthma into adulthood.
| |
|
| |
|
| There is a reduced occurrence of asthma in people who were breast-fed as babies. Current research suggests that the [[prevalence]] of childhood asthma has been increasing. According to the [[Centers for Disease Control and Prevention]]'s National Health Interview Surveys, some 9% of US children below 18 years of age had asthma in 2001, compared with just 3.6% in 1980 (see figure). The [[World Health Organization]] (WHO) reports that some 8% of the Swiss population suffers from asthma today, compared with just 2% some 25–30 years ago.<ref name=WHO>{{cite web | author=World Health Organization | authorlink=World Health Organization | title=Bronchial asthma: scope of the problem | url=http://www.who.int/entity/respiratory/asthma/scope/en/index.html}}</ref>
| | ==[[Asthma causes|Etiology]]== |
| Although asthma is more common in affluent countries, it is by no means a problem restricted to the affluent; the WHO estimate that there are between 15 and 20 million asthmatics in India. In the U.S., urban residents, Hispanics, and African Americans are affected more than the population as a whole. Globally, asthma is responsible for around 180,000 deaths annually.<ref name=WHO />
| |
|
| |
|
| On the remote South Atlantic island Tristan da Cunha, 50% of the population are asthmatics due to heredity transmission of a mutation in the gene CC16.
| | ==[[Asthma differential diagnosis|Differentiating Asthma from other Diseases]]== |
|
| |
|
| ===Socioeconomic factors=== | | ==[[Asthma diagnosis|Diagnosis]]== |
| The incidence of asthma is higher among low-income populations within a society (it is not more common in developed countries than developing countries [http://www.who.int/mediacentre/factsheets/fs307/en/]), which in the western world are disproportionately ethnic minorities, and more likely to live near industrial areas. Additionally, asthma has been strongly associated with the presence of cockroaches in living quarters, which is more likely in such neighborhoods.<ref name=AAAAAI>{{cite web | title=Patient/Public Education: Fast Facts - Asthma Demographics/Statistics | publisher= American Academy of Allergy Asthma & Immunology | url=http://www.aaaai.org/patients/resources/fastfacts/asthma_demographics.stm}}</ref>
| | [[Asthma history and symptoms|History and Symptoms]] | [[Asthma physical examination|Physical Examination]] | [[Asthma laboratory tests|Laboratory Test]] | [[Asthma pulmonary function test|Pulmonary Function Test]] | [[Asthma chest x ray|Chest X-Ray]] |
| | |
| Asthma incidence and quality of treatment varies among different racial groups, though this may be due to correlations with income (and thus affordability of health care) and geography. For example, Black Americans are less likely to receive outpatient treatment for asthma despite having a higher prevalence of the disease. They are much more likely to have emergency room visits or hospitalization for asthma, and are three times as likely to die from an asthma attack compared to whites. The prevalence of "severe persistent" asthma is also greater in low-income communities compared with communities with better access to treatment.<ref name="NIH2004">{{cite journal | author=National HAeart, Lung, and Blood Institute | title=Morbidity & Mortality: 2004 Chart Book On Cardiovascular, Lung, and Blood Diseases | year=May 2004 | publisher=National Institutes of Health}}</ref><ref name="CDC2002">{{cite web | author=National Center for Health Statistics | title=Asthma Prevalence, Health Care Use and Mortality, 2002 | year=07 April 2006 | publisher=Centers for Disease Control and Prevention | url=http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm}}</ref>
| |
| | |
| ===Asthma and athletics===
| |
| Asthma appears to be more prevalent in athletes than in the general population. One survey of participants in the 1996 Summer Olympic Games, in Atlanta, Georgia, U.S., showed that 15% had been diagnosed with asthma, and that 10% were on asthma medication. <ref name=olympics>Weiler JM, Layton T, Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. ''J Allergy Clin Immunol''. 1998;102(5):722-6. PMID 9819287</ref>
| |
| These statistics have been questioned on at least two bases. Athletes with mild asthma may be more likely to be diagnosed with the condition than non-athletes, because even subtle symptoms may interfere with their performance and lead to pursuit of a diagnosis. It has also been suggested that some professional athletes who do not suffer from asthma claim to do so in order to obtain special permits to use certain performance-enhancing drugs.
| |
| | |
| There appears to be a relatively high incidence of asthma in sports such as cycling, mountain biking, and long-distance [[running]], and a relatively lower incidence in weightlifting and diving. It is unclear how much of these disparities are from the effects of training in the sport, and from self-selection of sports that may appear to minimize the triggering of asthma.<!--
| |
| --><ref name=olympics /><!--
| |
| --><ref name=athletes>Helenius I, Haahtela T. Allergy and asthma in elite summer sport athletes. ''J Allergy Clin Immunol''. 2000;106(3):444-52 PMID 10984362</ref>
| |
| | |
| In addition, there exists a variant of asthma called [[exercise-induced asthma]] that shares many features with allergic asthma. It may occur either independently, or concurrent with the latter. Exercise studies may be helpful in diagnosing and assessing this condition.
| |
| | |
| ==Differential diagnosis==
| |
| Before diagnosing someone as asthmatic, [[differential diagnosis|alternative possibilities]] should be considered. A clinician taking a history should check whether the patient is using any known bronchoconstrictors (substances that cause narrowing of the airways, e.g., certain [[anti-inflammatory]] agents or [[beta-blockers]]).
| |
| | |
| [[Chronic obstructive pulmonary disease]], which closely resembles asthma, is correlated with more exposure to cigarette smoke, an older patient, less symptom reversibility after bronchodilator administration (as measured by [[spirometry]]), and decreased likelihood of family history of [[atopy]].
| |
| | |
| [[Pulmonary aspiration]], whether '''direct''' due to [[dysphagia]] (swallowing disorder) or '''indirect''' (due to acid reflux), can show similar symptoms to asthma. However, with aspiration, fevers might also indicate [[aspiration pneumonia]]. Direct aspiration (dysphagia) can be diagnosed by performing a Modified Barium Swallow test and treated with feeding therapy by a qualified speech therapist. If the aspiration is indirect (from acid reflux) then treatment directed at this is indicated.
| |
| | |
| A majority of children who are asthma sufferers have an identifiable [[allergy]] trigger. Specifically, in a 2004 study, 71% had positive test results for more than 1 allergen, and 42% had positive test results for more than 3 allergens.<ref>{{cite journal |last=Vargas |first=PA |title=Characteristics of children with asthma who are enrolled in a Head Start program |url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15356547&query_hl=23&itool=pubmed_docsum |journal= J Allergy Clin Immunol |date=September 2004 |pages=499–504 |pmid=15356547 }}</ref>
| |
| | |
| The majority of these triggers can often be identified from the history; for instance, asthmatics with [[hay fever]] or pollen allergy will have seasonal symptoms, those with allergies to pets may experience an abatement of symptoms when away from home, and those with [[occupational asthma]] may improve during leave from work. Occasionally, [[allergy#Diagnosis|allergy tests]] are warranted and, if positive, may help in identifying avoidable symptom triggers.
| |
| | |
| After a [[pulmonary function test]] has been carried out, radiological tests, such as a [[chest X-ray]] or [[computed tomography|CT scan]], may be required to exclude the possibility of other lung diseases. In some people, asthma may be triggered by [[gastroesophageal reflux disease]], which can be treated with suitable [[antacid]]s. Very occasionally, specialized tests after inhalation of [[methacholine challenge test|methacholine]] — or, even less commonly, [[histamine]] — may be performed.
| |
| | |
| Asthma is categorized by the United States [[National Heart, Lung and Blood Institute]] as falling into one of four categories: intermittent, mild persistent, moderate persistent and severe persistent. The diagnosis of "severe persistent asthma" occurs when symptoms are continual with frequent exacerbations and frequent nighttime symptoms, result in limited physical activity and when lung function as measured by PEV or FEV<sub>1</sub> tests is less than 60% predicted with PEF variability greater than 30%. | |
| | |
| ==Cause==
| |
| Asthma is caused by a complex interaction of environmental and genetic factors that researchers do not yet fully understand.<ref name=Martinez_geneenvir>{{cite journal |author=Martinez FD |title=Genes, environments, development and asthma: a reappraisal |journal=Eur Respir J |volume=29 |issue=1 |pages=179–84 |year=2007 |pmid=17197483 |doi=10.1183/09031936.00087906}}</ref> These factors can also influence how severe a person’s asthma is and how well they respond to medication.<ref>{{cite journal |author=Choudhry S, Seibold MA, Borrell LN "et al." |title=Dissecting complex diseases in complex populations: asthma in latino americans |journal=Proc Am Thorac Soc |volume=4 |issue=3 |pages=226–33 |year=2007 |pmid=17607004 |doi=10.1513/pats.200701-029AW}}</ref> As with other complex diseases, many environmental and genetic factors have been suggested as causes of asthma, but not all studies posing such claims have been verified by further studies. In addition, as researchers detangle the complex causes of asthma, it is becoming more evident that certain environmental and genetic factors may affect asthma only when combined.
| |
| | |
| ===Environmental===
| |
| Many environmental [[risk factor]]s have been associated with asthma development and morbidity in children, but a few stand out as well-replicated or that have a [[meta-analysis]] of several studies to support their direct association.
| |
| | |
| [[Passive smoking|Environmental tobacco smoke]], especially maternal cigarette smoking, is associated with high risk of asthma prevalence and asthma morbidity, wheeze, and respiratory infections.<ref name=Gold /> Poor [[air Quality Index|air quality]], from traffic pollution or high [[ozone]] levels, has been repeatedly associated with increased asthma [[morbidity]] and has a suggested association with asthma development that needs further research.<ref name=Gold>{{cite journal |author=Gold DR,Wright R |title=Population disparities in asthma |journal=Annu Rev Public Health |volume=26 |pages=89–113 |year=2005 |pmid=15760282 |doi=10.1146/annurev.publhealth.26.021304.144528}}</ref><ref name=childrens_health_study>{{cite web | url = http://www.arb.ca.gov/research/chs/chs.htm | title = California Children's Health Study}}</ref>
| |
| | |
| [[Caesarean section]]s have been associated with asthma when compared with vaginal birth; a meta-analysis found a 20% increase in asthma prevalence in children delivered by Cesarean section compared to those who were not. It was proposed that this is due to modified bacterial exposure during Cesarean section compared with vaginal birth, which modifies the immune system (as described by the hygiene hypothesis).<ref name=Thavagnanam />
| |
| | |
| Psychological [[stress (biological)|stress]], has long been suspected of being an asthma trigger, but only in recent decades has convincing scientific evidence substantiated this hypothesis. Rather than stress directly causing the asthma symptoms, it is thought that stress modulates the immune system to increase the magnitude of the airway inflammatory response to allergens and irritants.<ref name=Gold /><ref name="Chen2007">{{cite journal |author=Chen E, Miller GE |title=Stress and inflammation in exacerbations of asthma. |journal=Brain Behav Immun. |volume=21 |issue=8 |pages=993-9 |year=2007 |pmid=17493786 |doi=}}</ref>
| |
| | |
| Viral respiratory infections at an early age, along with siblings and day care exposure, may be protective against asthma, although there have been controversial results, and this protection may depend on genetic context.<ref name=Gold /><ref name="Thorax2006-Terttu">{{cite journal |author=Harju TH, Leinonen M, Nokso-Koivisto J, ''et al'' |title=Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma |journal=Thorax |volume=61 |issue=7 |pages=579–84 |year=2006 |pmid=16517571 |doi=10.1136/thx.2005.056291}}</ref><ref name="Cochrane2005-Richeldi">{{cite journal |author=Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG |title=Macrolides for chronic asthma |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD002997 |year=2005 |pmid=16235309 |doi=10.1002/14651858.CD002997.pub3}}</ref> [[Antibiotic]] use early in life has been linked to development of asthma in several examples; it is thought that antibiotics make one susceptible to development of asthma because they modify [[gut flora]], and thus the immune system (as described by the hygiene hypothesis).<ref name=Marra />
| |
| The [[hygiene hypothesis]] is an [[hypothesis]] about the cause of asthma and other allergic disease, and is supported by epidemiologic data for asthma. For example, asthma prevalence has been increasing in developed countries along with increased use of antibiotics, c-sections, and cleaning products.<ref name=Marra>{{cite journal |author=Marra F, Lynd L, Coombes M "et al." |title=Does antibiotic exposure during infancy lead to development of asthma?: a systematic review and metaanalysis |journal=Chest |volume=129 |issue=3 |pages=610–8 |year=2006 |pmid=16537858 |doi=10.1378/chest.129.3.610}}</ref><ref name=Thavagnanam>{{cite journal |author=Thavagnanam S, Fleming J, Bromley A, Shields MD, Cardwell, CR |title=A meta-analysis of the association between Caesarean section and childhood asthma |journal=Clin. And Exper. Allergy |volume=online ahead of print |year=2007 |doi=10.1111/j.1365-2222.2007.02780.x | pages = 629}}</ref><ref name=europe_study>{{cite web | author=Jeremy Laurance | url=http://www.belfasttelegraph.co.uk/health/article3056797.ece | title = Asthma blamed on cleaning sprays and air fresheners}}</ref> All of these things may negatively affect exposure to beneficial bacteria and other immune system modulators that are important during development, and thus may cause increased risk for asthma and allergy.
| |
| ===Genetic===
| |
| Over 100 [[gene]]s have been associated with asthma in at least one [[genetic association|genetic association study]].<ref name=Hoffjan>{{cite journal |author=Ober C,Hoffjan S |title=Asthma genetics 2006: the long and winding road to gene discovery |journal=Genes Immun |volume=7 |issue=2 |pages=95–100 |year=2006 |pmid=16395390 |doi=10.1038/sj.gene.6364284}}</ref> However, such studies must be repeated to ensure the findings are not due to chance. Through the end of 2005, 25 genes had been associated with asthma in six or more separate populations:<ref name=Hoffjan />
| |
| | |
| {{Multicol}}
| |
| <small>
| |
| * Glutathione S-transferase Mu 1 (GSTM1)
| |
| *[[Interleukin 10|IL10]]
| |
| *[[CTLA-4]]
| |
| *[[SPINK5]]
| |
| *[[Leukotriene C4 synthase|LTC4S]]
| |
| {{Multicol-break}}
| |
| <small>
| |
| * lymphotoxin alpha (LTA)
| |
| * GRPA
| |
| * NOD1
| |
| * CC16
| |
| * GSTP1
| |
| {{Multicol-break}}
| |
| <small>
| |
| *[[STAT6]]
| |
| *[[NOS1]]
| |
| *[[CCL5]]
| |
| *[[Thromboxane receptor|TBXA2R]]
| |
| *[[TGFB1]]
| |
| {{Multicol-break}}
| |
| <small>
| |
| *[[Interleukin 4|IL4]]
| |
| *[[Interleukin 13|IL13]]
| |
| *[[CD14]]
| |
| *[[Beta-2 adrenergic receptor|ADRB2]] (β-2 adrenergic receptor)
| |
| *[[HLA-DRB1]]
| |
| {{Multicol-break}}
| |
| <small>
| |
| *[[HLA-DQB1]]
| |
| *[[Tumor necrosis factors|TNF]]
| |
| * FCER1B
| |
| * Interleukin-4 receptor (IL4R)
| |
| *[[ADAM33]]
| |
| </small>
| |
| {{Multicol-end}}
| |
| | |
| Many of these genes are related to the immune system or to modulating inflammation. However, even among this list of highly replicated genes associated with asthma, the results have not been consistent among all of the populations that have been tested.<ref name=Hoffjan /> This indicates that these genes are not associated with asthma under every condition, and that researchers need to do further investigation to figure out the complex interactions that cause asthma. One theory is that asthma is a collection of several diseases, and that genes might have a role in only subsets of asthma. For example, one group of genetic differences ([[single nucleotide polymorphism]]s in [[Chromosome 17 (human)|17q21]]) was associated with asthma that develops in childhood.<ref name="pmid18923164">{{cite journal |author=Bouzigon E, Corda E, Aschard H, ''et al'' |title=Effect of 17q21 Variants and Smoking Exposure in Early-Onset Asthma |journal=The New England journal of medicine |volume= |issue= |pages= |year=2008 |month=October |pmid=18923164 |doi=10.1056/NEJMoa0806604 |url=}}</ref>
| |
| | |
| ===Gene-environment Interactions===
| |
| Research suggests that some genetic variants may only cause asthma when they are combined with specific environmental exposures, and otherwise may not be risk factors for asthma.<ref name=Martinez_geneenvir />
| |
| | |
| The genetic trait, CD14 [[single nucleotide polymorphism]] (SNP) C-159T and exposure to [[endotoxin]] (a bacterial product) are a well-replicated example of a gene-environment interaction that is associated with asthma. Endotoxin exposure varies from person to person and can come from several environmental sources, including environmental tobacco smoke, dogs, and farms. Researchers have found that risk for asthma changes based on a person’s [[genotype]] at CD14 C-159T and level of endotoxin exposure.<ref name=Martinez_CD14>{{cite journal |author=Martinez FD |title=CD14, endotoxin, and asthma risk: actions and interactions |journal=Proc Am Thorac Soc |volume=4 |issue=3 |pages=221–5 |year=2007 |pmid=17607003 |doi=10.1513/pats.200702-035AW}}</ref>
| |
| | |
| {| border="1"
| |
| |+ {{nowrap|'''CD14-endotoxin interaction based on CD14 SNP C-159T'''<ref name=Martinez_CD14 />}}
| |
| ! Endotoxin levels !! CC genotype !! TT genotype
| |
| |-
| |
| ! High exposure
| |
| | Low risk || High risk
| |
| |-
| |
| ! Low exposure
| |
| |High risk || Low risk
| |
| |}
| |
| | |
| ==Pathophysiology==
| |
| [[Image:Asthma before-after.png|thumb|470px|'''Inflamed airways and bronchoconstriction in asthma'''. Airways narrowed as a result of the inflammatory response cause wheezing.]]
| |
| ===Bronchoconstriction===
| |
| During an asthma episode, inflamed [[bronchiole|airways]] react to environmental triggers such as smoke, dust, or pollen. The airways narrow and produce excess [[mucus]], making it difficult to breathe.
| |
| In essence, asthma is the result of an [[immune response]] in the [[bronchial]] airways.<ref name=Maddox>Maddox L, Schwartz DA. The Pathophysiology of Asthma. ''Annu. Rev. Med.'' 2002, 53:477-98. PMID 11818486</ref>
| |
| | |
| The airways of asthmatics are "[[hypersensitivity|hypersensitive]]" to certain triggers, also known as ''stimuli'' (see below). In response to exposure to these triggers, the [[bronchi]] (large airways) contract into [[spasm]] (an "asthma attack"). [[Inflammation]] soon follows, leading to a further narrowing of the airways and excessive [[mucus]] production, which leads to coughing and other breathing difficulties.
| |
| | |
| ===Stimuli===
| |
| *[[Allergen]]ic air pollution, from nature, typically inhaled, which include waste from common household pests, such as the house dust mite and cockroach, grass pollen, mould spores, and pet [[epithelium|epithelial cells]];
| |
| *Indoor [[allergen]]ic air pollution from [[volatile organic compound]]s, including perfumes and perfumed products. Examples include soap, dishwashing liquid, laundry detergent, fabric softener, paper tissues, paper towels, toilet paper, shampoo, hairspray, hair gel, cosmetics, facial cream, sun cream, deodorant, cologne, shaving cream, aftershave lotion, air freshener and candles, and products such as oil-based paint.
| |
| *[[Medication]]s, including [[aspirin]],<ref name=Jenkins>Jenkins C, Costello J, Hodge L. [[Systematic review]] of prevalence of aspirin induced asthma and its implications for clinical practice. ''[[British Medical Journal|BMJ]]'' 2004;328:434. PMID 14976098</ref> [[beta blocker|β-adrenergic antagonist]]s (beta blockers), and [[penicillin]].
| |
| *[[Food allergy|Food allergies]] such as milk, [[peanut]]s, and eggs. However, asthma is rarely the only symptom, and not all people with food or other allergies have asthma.
| |
| *Use of fossil fuel related [[allergen]]ic air pollution, such as ozone, smog, summer smog, nitrogen dioxide, and sulfur dioxide, which is thought to be one of the major reasons for the high prevalence of asthma in [[Urban area|urban]] areas;
| |
| *Various industrial compounds and other chemicals, notably sulfites; [[chlorine|chlorinated]] swimming pools generate [[chloramine]]s—monochloramine (NH<sub>2</sub>Cl), dichloramine (NHCl<sub>2</sub>) and trichloramine (NCl<sub>3</sub>)—in the air around them, which are known to induce asthma.<ref name=Nemery>Nemery B, Hoet PH, Nowak D. Indoor swimming pools, water chlorination and respiratory health. ''Eur Respir J''. 2002;19(5):790-3. PMID 12030714</ref>
| |
| *Early childhood [[infection]]s, especially [[virus|viral]] respiratory infections. However, persons of any age can have asthma triggered by colds and other respiratory infections even though their normal stimuli might be from another category (e.g. pollen) and absent at the time of infection. 80% of asthma attacks in adults and 60% in children are caused by respiratory viruses.
| |
| *[[Exercise]], the effects of which differ somewhat from those of the other triggers;
| |
| *[[Allergen]]ic indoor air pollution from newsprint & other literature such as, Direct marketing / junk mail leaflets & glossy magazines (in some countries).
| |
| *[[Hormone|Hormonal]] changes in adolescent girls and adult women associated with their [[menstrual cycle]] can lead to a worsening of asthma. Some women also experience a worsening of their asthma during [[pregnancy]] whereas others find no significant changes, and in other women their asthma improves during their pregnancy.
| |
| *[[Stress (medicine)|Emotional stress]] which is poorly understood as a trigger.
| |
| *Cold weather can adversely affect breathing in asthmatics.<ref>[http://lungdiseases.about.com/od/faqaboutemphysema/f/cold_weather.htm about.com article]</ref>
| |
| | |
| ===Bronchial inflammation===
| |
| The mechanisms behind allergic asthma—i.e., asthma resulting from an [[immune response]] to inhaled [[allergen]]s—are the best understood of the causal factors. In both asthmatics and non-asthmatics, inhaled allergens that find their way to the inner [[bronchiole|airways]] are [[phagocytosis|ingested]] by a type of cell known as antigen presenting cells, or APCs. APCs then "present" pieces of the allergen to other [[immune system]] cells. In most people, these other immune cells ([[T helper cell|T<sub>H</sub>0 cells]]) "check" and usually ignore the allergen molecules. In asthmatics, however, these cells [[differentiation|transform]] into a different type of cell (T<sub>H</sub>2), for reasons that are not well understood. The resultant T<sub>H</sub>2 cells activate an important arm of the immune system, known as the [[humoral immunity|humoral immune system]]. The humoral immune system produces [[antibody|antibodies]] against the inhaled allergen. Later, when an asthmatic inhales the same allergen, these antibodies "recognize" it and activate a humoral response. [[Inflammation]] results: chemicals are produced that cause the airways to constrict and release more mucus, and the cell-mediated arm of the immune system is activated. The inflammatory response is responsible for the clinical manifestations of an asthma attack. The following section describes this complex series of events in more detail.
| |
| | |
| ===Pathogenesis===
| |
| The fundamental problem in asthma appears to be [[immunology|immunological]]: young children in the early stages of asthma show signs of excessive inflammation in their airways. [[Epidemiology|Epidemiological findings]] give clues as to the [[pathogenesis]]: the incidence of asthma seems to be increasing worldwide, and asthma is now very much more common in affluent countries.
| |
| | |
| In 1968 Andor Szentivanyi first described ''The Beta Adrenergic Theory of Asthma''; in which blockage of the Beta-2 receptors of pulmonary smooth muscle cells causes asthma.<!--
| |
| --><ref>{{cite journal | author=Szentivanyi, Andor | title=The Beta Adrenergic Theory of the Atopic Abnormality in Asthma | jounal=J.Allergy | year=1968}}</ref>
| |
| Szentivanyi's Beta Adrenergic Theory is a citation classic<ref name=Tribute>Lockey, Richard, In lasting tribute: Andor Szentivanyi, MD. ''J. Allergy and Clinical Immunology'', January, 2006</ref> and has been cited more times than any other article in the history of the Journal of Allergy.
| |
| | |
| In 1995 Szentivanyi and colleagues demonstrated that IgE blocks beta-2 receptors.<!--
| |
| --><ref>{{cite journal | author=Szentivanyi A., Ali K., Calderon EG., Brooks SM., Coffey RG., Lockey RF. | title=The ''in vitro'' effect of Imunnoglobulin E {IgE} on cyclic AMP concentrations in A549 human pulmonary epithelial cells with or without beta adrenergic stimulation | journal=J. Allergy Clin Immunol. | volume=91 | pages=379 | year=1993}} - Part of Abstracts from:<br/>
| |
| {{cite journal | author = | title = 50th Anniversary of the American Academy of Allergy and Immunology. 49th Annual Meeting. Chicago, Illinois, March 12–17, 1993. Abstracts. | journal = J Allergy Clin Immunol | volume = 91 | issue = 1 Pt 2 | pages = 141–379 | year = 1993 | id = PMID 8421135}}</ref>
| |
| Since overproduction of IgE is central to all atopic diseases, this was a watershed moment in the world of allergy.<!--
| |
| --><ref>{{cite book | editor=Kowalak JP, Hughes AS et al (eds) | title=Professional Guide To Diseases | edition=7th ed. | year=2001 | publisher=Springhouse}}</ref>
| |
| | |
| The Beta-Adrenergic Theory has been cited in the scholarship of such noted investigators as Richard F. Lockey (former President of the American Academy of Allergy, Asthma, and Immunology),<ref name=Richard_F_Lockey>{{cite web | url = http://www.worldallergy.org/professional/allergic_diseases_center/anaphylaxis/anaphylaxissynopsis.shtml | title = Anaphylaxis: Synopsis | accessmonthday = September 23 | accessyear = 2006 | last = Lockey | first = Richard F. | work = Allergic Diseases Resource Center | publisher = World Allergy Organization }}</ref> Charles Reed (Chief of Allergy at Mayo Medical School),<ref name=Charles_Reed>{{cite journal | first = J. J. | last = Ouellette | coauthors = C. E. Reed | year = 1967 | month = March | title = The effect of partial beta adrenergic blockade on the bronchial response of hay fever subjects to ragweed aerosol. | journal = Journal of Allergy | volume = 39 | issue = 3 | pages = 160-6 | id = {{PMID|5227155}}}}</ref> and Craig Venter (Human Genome Project).<ref name=Craig_Venter>{{cite journal | last = Fraser | first = Claire M. | coauthors = [[Craig Venter|J. Craig Venter]] | date = May 14, 1980 | title = The synthesis of beta-adrenergic receptors in cultured human lung cells: induction by glucocorticoids. | journal = Biochemical and Biophysical Research Communications | volume = 94 | issue = 1 | pages = 390–397 | doi = 10.1016/S0006-291X(80)80233-6 | id = {{PMID|6248064}} | url = http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WBK-4G0VNMJ-S8&_coverDate=05%2F14%2F1980&_alid=454587819&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6713&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=f3bc10fca4f32364a318857c0262f252 | format = PDF}}</ref>
| |
| | |
| Many studies have linked asthma, [[bronchitis]], and acute respiratory illnesses to [[Air pollution|air quality]] experienced by children.<ref name=asthma_air_quality>{{cite web | url = http://ewg.org/sites/asthmaindex/about/kidshealth.php | title = Asthma and Air Quality}}</ref> One of the largest of these studies is the California Children's Health Study.<ref name=childrens_health_study>{{cite web | url = http://www.arb.ca.gov/research/chs/chs.htm | title = California Children's Health Study}}</ref> From the press release [http://www.arb.ca.gov/newsrel/nr013102.htm]
| |
| | |
| This study showed that children in the high ozone communities who played three or more sports developed asthma at a rate three times higher than those in the low ozone communities. Because participation in some sports can result in a child drawing up to 17 times the “normal” amount of air into the lungs, young athletes are more likely to develop asthma.
| |
| | |
| Note that concentrations of ozone have risen steadily in Europe since 1870. [http://www.eoearth.org/image/Histconc.gif]
| |
| | |
| Another theory of [[pathogenesis]] is that asthma is a disease of hygiene. In nature, babies are exposed to [[bacteria]] and other [[antigen]]s soon after birth, "switching on" the T<sub>H</sub>1 [[lymphocyte]] cells of the [[immune system]] that deal with bacterial infection. If this stimulus is insufficient, as it may be in modern, clean environments, then T<sub>H</sub>2 cells predominate, and asthma and other allergic diseases may develop. This "[[hygiene hypothesis]]" may explain the increase in asthma in affluent populations. The T<sub>H</sub>2 lymphocytes and [[eosinophil]] cells that protect us against [[parasite]]s and other infectious agents are the same cells responsible for the allergic reaction. [[Charcot-Leyden crystals]] are formed when crystalline material in eosinophils coalesce. These crystals are significant in sputum samples of people with asthma. In the developed world, the [[parasite]]s that eosinophils are programmed to combat are now rarely encountered, but the immune response remains and is wrongly triggered in some individuals by certain allergens.
| |
| | |
| It has been postulated that some forms of asthma may be related to infection, in particular by ''[[Chlamydophila pneumoniae|Chlamydia pneumoniae]]''.<!--
| |
| --><ref name="Thorax2006-Terttu">{{cite journal | author=Terttu HH, Leinonen M, Nokso-Koivisto J, Korhonen T, Raty R, He Q, Hovi T, Mertsola J, Bloigu A, Rytila P, Saikku P | title=Non-random distribution of pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma | journal=Thorax | year=2006 | pages= | volume= | id=PMID 16517571}}</ref>
| |
| This issue remains controversial, as the relationship is not borne out by [[meta-analysis]] of the research.<!--
| |
| --><ref name="Cochrane2005-Richeldi">{{cite journal | author=Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG | title=Macrolides for chronic asthma | journal=Cochrane Database Syst Rev | year=2005 | pages=CD002997 | volume= | issue=4 | id=PMID 16235309}}</ref>
| |
| The correlation seems to be not with the onset, but rather with accelerated loss of lung function in adults with new onset of non-atopic asthma.<!--
| |
| --><ref name="JAllergyClinImmunol2005-Pasternack">{{cite journal | author=Pasternack R, Huhtala H, Karjalainen J | title=Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis | journal=J Allergy Clin Immunol | year=2005 | pages=1123–8 | volume=116 | issue=5 | id=PMID 16275386}}</ref>
| |
| One possible explanation is that some asthmatics may have altered immune response that facilitates long-term chlamydia pneumonia infection.<!--
| |
| --><ref name="PediatrAllergyImmunol2005-Ronchetti">{{cite journal | author=Ronchetti R, Biscione GL, Ronchetti F, Ronchetti MP, Martella S, Falasca C, Casini C, Barreto M, Villa MP | title=Why Chlamydia pneumoniae is associated with asthma and other chronic conditions? Suggestions from a survey in unselected 9 years old schoolchildren | journal=Pediatr Allergy Immunol | year=2005 | pages=145-50 | volume=16 | issue=2 | id=PMID 15787872}}</ref>
| |
| The response to targeting with [[macrolide]] antibiotics has been investigated, but the temporary benefit reported in some studies may reflect just their anti-inflammatory activities rather than their antimicrobic action.<!--
| |
| --><ref name="Cochrane2005-Richeldi" />
| |
| | |
| One group of researchers suggested that, in part, asthma has a neurogenic paroxysmal component,<!--
| |
| --><ref>{{cite web |author=Lomia M |title=Bronchial asthma as neurogenic paroxysmal and inflammatory disease -- Scientific background of effective use of anticonvulsants for pharmacotherapy of bronchial asthma |url=http://www.asthma.ge/Doctors.htm |date=March 20, 2006}}</ref>
| |
| and that several anti-eleptic drugs have an effect. However only one paper<!--
| |
| --><ref name="pmid16597501">{{cite journal |author=Lomia M, Tchelidze T, Pruidze M |title=Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine |journal=Respiratory medicine |volume=100 |issue=11 |pages=1988-96 |year=2006 |pmid=16597501 |doi=10.1016/j.rmed.2006.02.018}}</ref>
| |
| has been published as listed by [[PubMed]] and its conclusions criticized.<!--
| |
| --><ref name="pmid17223330">{{cite journal |author=Singh N |title=Carbamazepine in asthma: first do no harm! |journal=Respiratory medicine |volume=101 |issue=3 |pages=676; author reply 677-8 |year=2007 |pmid=17223330 |doi=10.1016/j.rmed.2006.11.025}}<br>'''Related warnings:'''
| |
| * {{cite journal |author=Lee T, Cochrane GM, Amlot P |title=Pulmonary eosinophilia and asthma associated with carbamazepine |journal=British medical journal (Clinical research ed.) |volume=282 |issue=6262 |pages=440 |year=1981 |pmid=6780065 |doi= |url=http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=1504286&pageindex=1 |format=Scanned image}}
| |
| * {{cite journal |author=Lewis IJ, Rosenbloom L |title=Glandular fever-like syndrome, pulmonary eosinophilia and asthma associated with carbamazepine |journal=Postgraduate medical journal |volume=58 |issue=676 |pages=100-1 |year=1982 |pmid=7100019 |doi=}}</ref>
| |
| | |
| A study conducted by the National Jewish Medical and Research Center concluded that overweight and obesity are associated with a dose-dependent increase in the odds of incident asthma in men and women, suggesting asthma incidence could be reduced by interventions targeting overweight and obesity. <ref>journal=American Journal of Respiratory and Critical Care Medicine | volume=175 |pages=661-666 | year=2007 |</ref>
| |
| | |
| ===Asthma and sleep apnea===
| |
| {{main|sleep apnea}}
| |
| It is recognized with increasing frequency, that patients who have both obstructive sleep apnea (OSA) and bronchial asthma, often improve tremendously when the sleep apnea is diagnosed and treated.<ref name=sleep_anpea1>{{cite press release | title = Breathing disorders during sleep are common among asthmatics, may help predict severe asthma | publisher = University of Michigan Health System | date = May 25, 2005 | url = http://www.med.umich.edu/opm/newspage/2005/asthmasleep.htm }}</ref> [[CPAP]] is not effective in patients with nocturnal asthma only.<ref name=CPAP_not_an_anti-asthmatic>{{cite web | url = http://www.sleepapnea.org/resources/pubs/asthma-osa.html | title = Asthma and OSA | accessmonthday = September 23 | accessyear = 2006 | last = Basner | first = Robert C. | work = ASAA Resources > Publications | publisher = American Sleep Apnea Association}}</ref>
| |
| | |
| ===Asthma and gastro-esophageal reflux disease===
| |
| {{main|Gastroesophageal Reflux Disease}}
| |
| If gastro-esophageal reflux disease is present, the patient may have repetitive episodes of acid aspiration, which results in airway inflammation and "irritant-induced" asthma. GERD may be common in difficult-to-control asthma, but generally speaking, treating it does not seem to affect the asthma.<ref name=Leggett_et_al_2005>{{cite journal | last = Leggett | first = Julian J. | coauthors = Brian T. Johnston, Moyra Mills, Jackie Gamble, and Liam G. Heaney | year = 2005 | month = April | title = Prevalence of Gastroesophageal Reflux in Difficult Asthma | journal = Chest | volume = 127 | issue = 4 | pages = 1227–1231 | id = {{PMID|15821199}} | url = http://www.chestjournal.org/cgi/content/full/127/4/1227}}</ref>
| |
| | |
| ==Signs and symptoms==
| |
| In some individuals asthma is characterized by chronic respiratory impairment. In others it is an intermittent illness marked by episodic symptoms that may result from a number of triggering events, including upper respiratory infection, stress, airborne allergens, air pollutants (such as smoke or traffic fumes), or exercise. Some or all of the following symptoms may be present in those with asthma: dyspnea, wheezing, stridor, coughing, an inability for physical exertion. Some asthmatics that have severe shortness of breath and tightening of the lungs never wheeze or have stridor and their symptoms may be confused with a [[COPD]]-type disease.
| |
|
| |
| An acute exacerbation of asthma is referred to as an ''asthma attack''. The clinical hallmarks of an attack are shortness of breath ([[dyspnea]]) and either [[wheeze|wheezing]] or [[stridor]].<ref name=McFadden>{{cite book | author = McFadden ER, Jr | chapter = Asthma | title = Harrison's Principles of Internal Medicine (Kasper DL, Fauci AS, Longo DL, ''et al'' (eds)) | edition = 16th ed. | pages = 1508–16 | location = New York | publisher = McGraw-Hill | year = 2004}}</ref> Although the former is "often regarded as the ''sine qua non'' of asthma,<ref name=McFadden /> some patients present primarily with [[cough]]ing, and in the late stages of an attack, air motion may be so impaired that no wheezing may be heard. When present the cough may sometimes produce clear [[sputum]]. The onset may be sudden, with a sense of constriction in the chest, breathing becomes difficult, and wheezing occurs (primarily upon expiration, but can be in both [[Respiration (physiology)|respiratory]] phases).
| |
| | |
| [[Sign (medicine)|Signs]] of an asthmatic episode include [[wheeze|wheezing]], rapid breathing ([[tachypnea]]), prolonged expiration, a rapid heart rate ([[tachycardia]]), rhonchus lung sounds (audible through a [[stethoscope]]), and over-inflation of the chest. During a serious asthma attack, the accessory [[muscle]]s of respiration (sternocleidomastoid and scalene muscles of the neck) may be used, shown as in-drawing of [[biological tissue|tissue]]s between the ribs and above the [[sternum]] and [[clavicle]]s, and the presence of a [[paradoxical pulse]] (a pulse that is weaker during inhalation and stronger during exhalation).
| |
| | |
| During very severe attacks, an asthma sufferer can [[cyanosis|turn blue]] from lack of oxygen, and can experience [[chest pain]] or even loss of [[consciousness]]. Just before loss of consciousness, there is a chance that the patient will feel numbness in the limbs and palms may start to sweat. Feet may become icy cold. Severe asthma attacks, which may not be responsive to standard treatments (''[[status asthmaticus]]''), are life-threatening and may lead to respiratory arrest and death. Despite the severity of symptoms during an asthmatic episode, between attacks an asthmatic may show few or even no signs of the disease.<ref>{{cite book |last=Longmore |first=Murray ''et al'' |title=Oxford Handbook of Clinical Medicine |publisher=Oxford University Press |location= |edition=7<sup>th</sup> ed.|year=2007 |pages= |isbn=978-0198568377 |oclc= |doi=}}</ref>
| |
| | |
| ==Diagnosis==
| |
| Asthma is defined simply as reversible airway obstruction. Reversibility occurs either spontaneously or with treatment. The basic measurement is [[peak expiratory flow rate|peak flow rates]] and the following diagnostic criteria are used by the [[British Thoracic Society]]:<ref>{{cite journal |author=Pinnock H, Shah R|title=Asthma|journal=Br Med J|year=2007|volume=334|issue=7598|pages=847–50|doi=10.1136/bmj.39140.634896.BE}}</ref>
| |
| *≥20% difference on at least three days in a week for at least two weeks;
| |
| *≥20% improvement of peak flow following treatment, for example:
| |
| **10 minutes of inhaled β-agonist (e.g., [[salbutamol]]);
| |
| **six week of inhaled [[corticosteroid]] (e.g., [[Beclometasone dipropionate|beclometasone]]);
| |
| **14 days of 30mg [[prednisolone]].
| |
| *≥20% decrease in peak flow following exposure to a trigger (e.g., exercise).
| |
| | |
| In many cases, a physician can [[diagnosis|diagnose]] asthma on the basis of typical findings in a patient's clinical history and examination. Asthma is strongly suspected if a patient suffers from [[eczema]] or other [[allergy|allergic]] conditions—suggesting a general [[atopy|atopic constitution]]—or has a [[Family history (medicine)|family history]] of asthma. While measurement of airway function is possible for adults, most new cases are diagnosed in children who are unable to perform such tests. Diagnosis in children is based on a careful compilation and analysis of the patient's [[medical history]] and subsequent improvement with an inhaled [[bronchodilator]] medication. In adults, diagnosis can be made with a [[peak flow meter]] (which tests airway restriction), looking at both the diurnal [[Circadian rhythm|variation]] and any reversibility following inhaled [[bronchodilator]] [[Asthma#Rapid relief|medication]].
| |
| | |
| Testing peak flow at rest (or baseline) and after exercise can be helpful, especially in young asthmatics who may experience only [[exercise-induced asthma]]. If the diagnosis is in doubt, a more formal [[spirometry|lung function test]] may be conducted. Once a diagnosis of asthma is made, a patient can use [[peak flow meter]] testing to monitor the severity of the disease.
| |
| | |
| In the Emergency Department doctors may use a [[capnography]] PMID 16187465 which measures the amount of exhaled [[carbon dioxide]] along with [[pulse oximetry]] which shows the amount of oxygen dissolved in the blood, to determine the severity of an asthma attack as well as the response to treatment.
| |
|
| |
|
| ==Treatment== | | ==Treatment== |
| | [[Asthma emergency management|Emergency Management]] | [[Asthma medical therapy|Medical Therapy]] | [[Asthma alternative and complementary medicine|Alternative and Complementary Medicine]] |
|
| |
|
| There is no cure for asthma. Doctors have only found ways to prevent attacks and relieve the symptoms such as tightness of the chest and trouble breathing.
| | ==[[Asthma secondary prevention|Secondary Prevention]]== |
| | |
| The most effective treatment for asthma is identifying triggers, such as pets or aspirin, and limiting or eliminating exposure to them. [[Desensitization (medicine)|Desensitization]] to allergens has been shown to be a treatment option for certain patients.<ref>American Journal of Respiratory and Critical Care Medicine 1995;151:969–74.</ref>
| |
| | |
| As is common with respiratory disease, [[tobacco smoking|smoking]] is believed to adversely affect asthmatics in several ways, including an increased severity of symptoms, a more rapid decline of lung function, and decreased response to preventive medications.<ref name=thomson>Thomson NC, Spears M. The influence of smoking on the treatment response in patients with asthma. ''Curr Opin Allergy Clin Immunol''. 2005;5(1):57–63. PMID 15643345</ref> Automobile emissions are considered an even more significant cause and aggravating factor. [http://www.ewg.org/sites/asthmaindex/youcan/regulators.php]
| |
| Asthmatics who smoke or who live near traffic [http://news.bbc.co.uk/1/hi/health/4368093.stm] typically require additional medications to help control their disease. Furthermore, exposure of both non-smokers and smokers to wood smoke, gas stove fumes and second-hand smoke is detrimental, resulting in more severe asthma, more [[emergency room]] visits, and more asthma-related hospital admissions.<ref name=eisner>Eisner MD, Yelin EH, Katz PP, ''et al.'' Exposure to indoor combustion and adult asthma outcomes: environmental tobacco smoke, gas stoves, and wood-smoke. ''Thorax''. 2002;57(11):973-8. PMID 12403881</ref>
| |
| Smoking cessation and avoidance of second-hand smoke is strongly encouraged in asthmatics.<ref name=epr2>National Asthma Education and Prevention Program. ''Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma''. National Institutes of Health pub no 97–4051. Bethesda, MD, 1997. ([http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf PDF])</ref>
| |
| | |
| The specific medical treatment recommended to patients with asthma depends on the severity of their illness and the frequency of their symptoms. Specific treatments for asthma are broadly classified as relievers, preventers and emergency treatment. The ''Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma'' (EPR-2)<!--
| |
| --><ref name=epr2 />
| |
| of the U.S. National Asthma Education and Prevention Program, and the ''British Guideline on the Management of Asthma''<!--
| |
| --><ref name=SIGN>British Thoracic Society & Scottish Intercollegiate Guidelines Network (SIGN). ''British Guideline on the Management of Asthma''. Guideline No. 63. Edinburgh:SIGN; 2004. ([http://www.sign.ac.uk/guidelines/fulltext/63/index.html HTML], [http://www.sign.ac.uk/pdf/sign63.pdf Full PDF], [http://www.sign.ac.uk/pdf/qrg63.pdf Summary PDF])</ref>
| |
| are broadly used and supported by many doctors. On August 29, 2007 the final ''Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma'' was officially released. Bronchodilators are recommended for short-term relief in all patients. For those who experience occasional attacks, no other medication is needed. For those with mild persistent disease (more than two attacks a week), low-dose inhaled glucocorticoids or alternatively, an oral leukotriene modifier, a mast-cell stabilizer, or theophylline may be administered. For those who suffer daily attacks, a higher dose of glucocorticoid in conjunction with a long-acting inhaled β-2 agonist may be prescribed; alternatively, a leukotriene modifier or theophylline may substitute for the β-2 agonist. In severe asthmatics, oral glucocorticoids may be added to these treatments during severe attacks.
| |
| | |
| For those in whom exercise can trigger an asthma attack ([[exercise-induced asthma]]), higher levels of ventilation and cold, dry air tend to exacerbate attacks. For this reason, activities in which a patient breathes large amounts of cold air, such as skiing and running, tend to be worse for asthmatics, whereas swimming in an indoor, heated pool, with warm, humid air, is less likely to provoke a response.<!--
| |
| --><ref name=McFadden />
| |
| | |
| Researchers at Harvard Medical School (HMS) have come up with convincing evidence that the answer to what causes asthma lies in a special type of natural "killer" cell. This finding means that physicians may not be treating asthma sufferers with the right kinds of drugs. For example, natural killer T cells seem to be resistant to the corticosteroids in widely used inhalers.<ref name=Harvard_cracks_asthma>{{cite news | first = William J. | last = Cromie | title = Researchers uncover cause of asthma | url = http://www.news.harvard.edu/gazette/2006/03.16/01-asthma.html | work = Harvard University Gazette | publisher = Harvard News Office | date = 2006-03-16 }}</ref>
| |
| | |
| ===Relief medication===
| |
| Symptomatic control of episodes of wheezing and shortness of breath is generally achieved with fast-acting [[bronchodilator]]s. These are typically provided in pocket-sized, metered-dose [[inhaler]]s (MDIs). In young sufferers, who may have difficulty with the coordination necessary to use inhalers, or those with a poor ability to hold their breath for 10 seconds after inhaler use (generally the elderly), an [[asthma spacer]] (see top image) is used. The spacer is a plastic cylinder that mixes the medication with air in a simple tube, making it easier for patients to receive a full dose of the drug and allows for the active agent to be dispersed into smaller, more fully inhaled bits. A [[nebulizer]] which provides a larger, continuous dose can also be used. Nebulizers work by vaporizing a dose of medication in a saline solution into a steady stream of foggy vapour, which the patient inhales continuously until the full dosage is administered. There is no clear evidence, however, that they are more effective than inhalers used with a spacer. Nebulizers may be helpful to some patients experiencing a severe attack. Such patients may not be able to inhale deeply, so regular inhalers may not deliver medication deeply into the lungs, even on repeated attempts. Since a nebulizer delivers the medication continuously, it is thought that the first few inhalations may relax the airways enough to allow the following inhalations to draw in more medication.
| |
| | |
| Relievers include:
| |
| * Short-acting, selective [[Beta2-adrenergic receptor agonist|beta<sub>2</sub>-adrenoceptor agonists]], such as [[salbutamol]] (''albuterol'' [[United States Adopted Name|USAN]]), [[levalbuterol]], [[terbutaline]] and [[bitolterol]].<br/>[[Tremor]]s, the major side effect, have been greatly reduced by inhaled delivery, which allows the drug to target the lungs specifically; oral and injected medications are delivered throughout the body. There may also be [[cardiac]] side effects at higher doses (due to Beta-1 agonist activity), such as elevated heart rate or blood pressure; with the advent of selective agents, these side effects have become less common. Patients must be cautioned against using these medicines too frequently, as with such use their efficacy may decline, producing [[desensitization]] resulting in an exacerbation of symptoms which may lead to refractory asthma and death.
| |
| * Older, less selective [[adrenergic receptor|adrenergic agonists]], such as inhaled [[epinephrine]] and [[ephedrine]] tablets, have also been used. Cardiac side effects occur with these agents at either similar or lesser rates to albuterol.<!--
| |
| --><ref name=Hendeles>Hendeles L, Marshik PL, ''et al.'' Response to nonprescription epinephrine inhaler during nocturnal asthma. ''Ann Allergy Asthma Immunol.'' 2005 Dec;95(6):530-4. PMID 16400891</ref> <!--
| |
| --><ref name=Rodrigo>Rodrigo GJ, Nannini LJ. Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-analysis of randomized trials. ''Am J Emerg Med.'' 2006 Mar;24(2):217-22. PMID 16490653</ref> When used solely as a relief medication, inhaled epinephrine has been shown to be an effective agent to terminate an acute asthmatic exacerbation.<ref name="Hendeles" /> In emergencies, these drugs were sometimes administered by injection. Their use via injection has declined due to related adverse effects.
| |
| *[[Anticholinergic]] medications, such as [[ipratropium bromide]] may be used instead. They have no cardiac side effects and thus can be used in patients with heart disease; however, they take up to an hour to achieve their full effect and are not as powerful as the β<sub>2</sub>-adrenoreceptor agonists.
| |
| * Inhaled [[glucocorticoids]] are usually considered preventive medications; however, a [[randomized controlled trial]] has demonstrated the benefit of 250 microg [[beclomethasone]] when taken as an as-needed combination inhaler with 100 microg of [[albuterol]].<ref name="pmid17507703">Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, Fabbri LM; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356:2040-52. PMID 17507703</ref>
| |
| | |
| ===Prevention medication===
| |
| Current treatment protocols recommend prevention medications such as an inhaled [[corticosteroid]], which helps to suppress [[inflammation]] and reduces the swelling of the lining of the airways, in anyone who has frequent (greater than twice a week) need of relievers or who has severe symptoms. If symptoms persist, additional preventive drugs are added until the asthma is controlled. With the proper use of prevention drugs, asthmatics can avoid the complications that result from overuse of relief medications.
| |
| | |
| Asthmatics sometimes stop taking their preventive medication when they feel fine and have no problems breathing. This often results in further attacks, and no long-term improvement.
| |
| | |
| Preventive agents include the following.
| |
| * Inhaled [[glucocorticoid]]s are the most widely used of the prevention medications and normally come as inhaler devices ([[ciclesonide]], [[beclomethasone]], [[budesonide]], [[flunisolide]], [[fluticasone]], [[mometasone furoate|mometasone]], and [[triamcinolone]]).<br/>Long-term use of corticosteroids can have many side effects including a redistribution of fat, increased [[appetite]], blood [[glucose]] problems and weight gain. In particular high doses of steroids may cause [[osteoporosis]]. For this reasons inhaled steroids are generally used for prevention, as their smaller doses are targeted to the lungs unlike the higher doses of oral preparations. Nevertheless, patients on high doses of inhaled steroids may still require prophylactic treatment to prevent osteoporosis.<br/>Deposition of steroids in the mouth may cause a [[dysphonia|hoarse voice]] or oral thrush (due to decreased immunity). This may be minimised by rinsing the mouth with water after inhaler use, as well as by using a [[Asthma spacer|spacer]] which increases the amount of drug that reaches the lungs.
| |
| * [[Leukotriene]] modifiers ([[montelukast]], [[zafirlukast]], [[pranlukast]], and [[zileuton]]).
| |
| * [[Mast cell]] stabilizers ([[cromoglicate]] (cromolyn), and [[nedocromil]]).
| |
| * Antimuscarinics/anticholinergics ([[ipratropium]], oxitropium, and [[tiotropium]]), which have a mixed reliever and preventer effect. (These are rarely used in preventive treatment of asthma, except in patients who do not tolerate beta-2-agonists.)
| |
| * Methylxanthines ([[theophylline]] and [[aminophylline]]), which are sometimes considered if sufficient control cannot be achieved with inhaled glucocorticoids and long-acting β-agonists alone.
| |
| * [[Antihistamine]]s, often used to treat allergic symptoms that may underlie the chronic inflammation. In more severe cases, [[hyposensitization]] ("allergy shots") may be recommended.
| |
| * [[Omalizumab]], an [[immunoglobulin E|IgE]] blocker; this can help patients with severe allergic asthma that does not respond to other drugs. However, it is expensive and must be injected.
| |
| * [[Methotrexate]] is occasionally used in some difficult-to-treat patients.
| |
| * If chronic acid indigestion ([[Gastroesophageal reflux disease|GERD]]) contributes to a patient's asthma, it should also be treated, because it may prolong the respiratory problem.
| |
| | |
| Additionally, the antidepressant [[tianeptine]] has shown significant efficacy in children with asthma.
| |
| | |
| ===Long-acting β<sub>2</sub>-agonists===
| |
| [[Image:AsthmaInhaler.jpg|thumb|180px|A typical [[inhaler]], of [[salmeterol|Serevent (salmeterol)]], a long-acting bronchodilator.]]
| |
| Long-acting bronchodilators (LABD) are similar in structure to short-acting selective beta<sub>2</sub>-adrenoceptor agonists, but have much longer sidechains resulting in a 12-hour effect, and are used to give a smoothed symptomatic relief (used morning and night). While patients report improved symptom control, these drugs do not replace the need for routine preventers, and their slow onset means the short-acting dilators may still be required. In November of 2005, the American [[Food and Drug Administration|FDA]] released a health advisory alerting the public to findings that show the use of long-acting β<sub>2</sub>-agonists could lead to a worsening of symptoms, and in some cases death.<!--
| |
| --><ref name=FDA"LABD">{{cite web | year=2006-03-03 | title=Serevent Diskus, Advair Diskus, and Foradil Information (Long Acting Beta Agonists) - Drug information | publisher=FDA | url=http://www.fda.gov/cder/drug/infopage/LABA/default.htm}}</ref>
| |
| | |
| Currently available [[long acting beta-adrenoceptor agonist|long-acting beta<sub>2</sub>-adrenoceptor agonists]] include [[salmeterol]], [[formoterol]], [[bambuterol]], and sustained-release oral [[albuterol]]. Combinations of inhaled steroids and long-acting bronchodilators are becoming more widespread; the most common combination currently in use is fluticasone/salmeterol (Advair in the United States, and Seretide in the United Kingdom). Another combination is [[budesonide]]/[[formoterol]] which is commercially known as symbicort.
| |
| | |
| A recent meta-analysis of the roles of long-acting beta-agonists may indicate a danger to asthma patients. "These agents can improve symptoms through bronchodilation at the same time as increasing underlying inflammation and bronchial hyper-responsiveness, thus worsening asthma control without any warning of increased symptoms," said Shelley Salpeter in a Cornell study. The study goes on to say that "Three common asthma inhalers containing the drugs salmeterol or formoterol may be causing four out of five US asthma-related deaths per year and should be taken off the market".<ref name=Down_with_Serevent>{{cite web | first = Krishna | last = Ramanujan | title = Common asthma inhalers cause up to 80 percent of asthma-related deaths, Cornell and Stanford researchers assert | url = http://www.news.cornell.edu/stories/June06/AsthmaDeaths.kr.html | work = Cornell Chronicle Online | publisher = Cornell News Service }}</ref> This assertion has drawn criticism from many asthma specialists for being inaccurate. As Dr. Hal Nelson points out in a recent letter to the Annals of Internal Medicine,<br/><br/>''"Salpeter and colleagues also assert that salmeterol may be responsible for 4000 of the 5000 asthma-related deaths that occur in the United States annually. However, when salmeterol was introduced in 1994, more than 5000 asthma-related deaths occurred per year. Since the peak of asthma deaths in 1996, salmeterol sales have increased about 5-fold, while overall asthma mortality rates have decreased by about 25%, despite a continued increase in asthma diagnoses. In fact, according to the most recent data from the National Center for Health Statistics, U.S. asthma mortality rates peaked in 1996 (with 5667 deaths) and have decreased steadily since. The last available data, from 2004, indicate that 3780 deaths occurred. Thus, the suggestion that a vast majority of asthma deaths could be attributable to LABA use is inconsistent with the facts."''
| |
| | |
| Dr. Salpeter has since tempered her comments regarding LABAs.
| |
| | |
| ===Emergency treatment===
| |
| When an asthma attack is unresponsive to a patient's usual medication, other treatments are available to the physician or hospital:<!--
| |
| --><ref name=rodrigo>Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. ''Chest''. 2004;125(3):1081-102. PMID 15006973</ref>
| |
| * [[oxygen]] to alleviate the hypoxia (but not the asthma ''per se'') that results from extreme asthma attacks;
| |
| * nebulized [[salbutamol]] or [[terbutaline]] (short-acting beta-2-agonists), often combined with ipratropium (an anticholinergic);
| |
| * systemic steroids, oral or intravenous ([[prednisone]], [[prednisolone]], [[methylprednisolone]], [[dexamethasone]], or hydrocortisone). Some research has looked into an alternative inhaled route.<ref>{{cite journal |author=Rodrigo G |title=Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma |journal=Am J Respir Crit Care Med |volume=171 |issue=11 |pages=1231–6 |year=2005 |pmid=15764724}}</ref>
| |
| * other bronchodilators that are occasionally effective when the usual drugs fail:
| |
| ** intravenous salbutamol
| |
| ** nonspecific beta-agonists, injected or inhaled ([[epinephrine]], isoetharine, [[isoproterenol]], [[metaproterenol]]);
| |
| ** anticholinergics, IV or nebulized, with systemic effects ([[glycopyrrolate]], [[atropine]], [[ipratropium]]);
| |
| ** methylxanthines ([[theophylline]], [[aminophylline]]);
| |
| ** inhalation anesthetics that have a bronchodilatory effect ([[isoflurane]], [[halothane]], [[enflurane]]);
| |
| ** the dissociative anaesthetic [[ketamine]], often used in [[endotracheal tube]] induction
| |
| ** [[magnesium sulfate]], intravenous; and
| |
| * intubation and mechanical ventilation, for patients in or approaching respiratory arrest.
| |
| * Heliox, a mixture of helium and oxygen, may be used in a hospital setting. It has a more laminar flow than ambient air and moves more easily through constricted airways
| |
| | |
| ===Alternative and complementary medicine===
| |
| Many asthmatics, like those who suffer from other chronic disorders, use [[Alternative medicine|alternative treatments]]; surveys show that roughly 50% of asthma patients use some form of unconventional therapy.<!--
| |
| --><ref name=blanc>Blanc PD, Trupin L, Earnest G, ''et al.'' Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. ''Chest''. 2001;120(5):1461–7. PMID 11713120</ref><!--
| |
| --><ref name=shenfield>Shenfield G, Lim E, Allen H. Survey of the use of complementary medicines and therapies in children with asthma. ''J Paediatr Child Health''. 2002;38(3):252-7. PMID 12047692</ref>
| |
| There are little data to support the effectiveness of most of these therapies. A [[Cochrane Collaboration|Cochrane]] [[Evidence-based medicine|systematic review]] of acupuncture for asthma found no evidence of efficacy.<!--
| |
| --><ref name=mccartney>McCarney RW, Brinkhaus B, Lasserson TJ, ''et al.'' Acupuncture for chronic asthma. ''Cochrane Database Syst Rev''. 2004;(1):CD000008. PMID 14973944</ref>
| |
| A similar review of [[air ioniser]]s found no evidence that they improve asthma symptoms or benefit lung function; this applied equally to positive and negative ion generators.<!--
| |
| --><ref name=blackhall>Blackhall K, Appleton S, Cates CJ. Ionisers for chronic asthma. ''Cochrane Database Syst Rev.'' 2003;(3):CD002986 PMID 12917939</ref>
| |
| A study of "manual therapies" for asthma, including osteopathic, [[chiropractic]], physiotherapeutic and [[respiratory therapy|respiratory therapeutic]] maneuvers, found there is insufficient evidence to support or refute their use in treating asthma;<!--
| |
| --><ref name=hondras>Hondras MA, Linde K, Jones AP. Manual therapy for asthma. ''Cochrane Database Syst Rev''. 2005;(2):CD001002. PMID 15846609</ref>
| |
| these maneuvers include various osteopathic and chiropractic techniques to "increase movement in the rib cage and the spine to try and improve the working of the lungs and circulation"; chest tapping, shaking, vibration, and the use of "postures to help shift and cough up phlegm." On the other hand, one [[meta-analysis]] found that homeopathy has a potentially mild benefit in reducing symptom intensity;<!--
| |
| --><ref name=reilly>Reilly D, Taylor MA, Beattie NG, ''et al.'' Is evidence for homoeopathy reproducible? ''Lancet.'' 1994;344(8937):1601–6. PMID 7983994</ref>
| |
| however, the number of patients involved in the analysis was small, and subsequent studies have not supported this finding.<!--
| |
| --><ref name=white>White A, Slade P, Hunt C, ''et al.'' Individualised homeopathy as an adjunct in the treatment of childhood asthma: a randomised placebo controlled trial. ''Thorax.'' 2003;58(4):317-21. PMID 12668794</ref>
| |
| Several small trials have suggested some benefit from various yoga practices, ranging from integrated yoga programs<!--
| |
| --><ref name=nagendra>Nagendra HR, Nagarathna R. An integrated approach of yoga therapy for bronchial asthma: a 3-54-month prospective study. ''J Asthma.'' 1986;23(3):123-37. PMID 3745111</ref>
| |
| —"yogasanas, Pranayama, meditation, and kriyas"—to ''sahaja'' yoga,<!--
| |
| --><ref name=manocha>Manocha R, Marks GB, Kenchington P, ''et al.'' Sahaja yoga in the management of moderate to severe asthma: a randomised controlled trial. ''Thorax.'' 2002;57(2):110-5. PMID 11828038</ref> a form of meditation.
| |
| | |
| The [[Buteyko method]], a Russian therapy based on breathing exercises, has been investigated. A randomized, controlled trial of just 39 patients in 1998 showed a substantial reduction in the need for beta-agonists and a 50% reduction in the need for inhaled steroids. Quality of life scores improved significantly as people were less afraid of their condition and more confident of the future. Lung function remained the same despite the decrease in medication.<!--
| |
| --><ref name=bowler>Bowler SD, Green A, Mitchell CA. Buteyko breathing techniques in asthma: a blinded randomised controlled trial. ''Med J Aust''. 1998;169(11-12):575-8. PMID 9887897. [http://www.mja.com.au/public/issues/xmas98/bowler/bowler.html Free full text]</ref>
| |
| A trial in New Zealand in 2000 showed an 85% reduction in the use of beta-agonist medication and a 50% reduction in inhaled steroid use after six months.<!--
| |
| --><ref name=mchugh>McHugh P, Aitcheson F, Duncan B, Houghton F. Buteyko Breathing Technique for asthma: an effective intervention. ''NZ Med J. '' 2003;116:1187 PMID 14752538. [http://www.nzma.org.nz/journal/116-1187/710/ Free full text]</ref>
| |
| | |
| Given that some [[Hookworm#Hookworm in therapy|research]] has identified a negative association between helminth infection ([[hookworm]]) and asthma and hay fever,<!--
| |
| --><ref name="pmid12100049">{{cite journal |author=Huang SL, Tsai PF, Yeh YF |title=Negative association of Enterobius infestation with asthma and rhinitis in primary school children in Taipei |journal=Clin. Exp. Allergy |volume=32 |issue=7 |pages=1029-32 |year=2002 |pmid=12100049 |doi=}}</ref>
| |
| some have suggested that hookworm infestation, although not medically sanctioned, would cure asthma. There is both anectdotal evidence<!--
| |
| --><ref name="BBC News">{{cite news | title=Worm infestation 'beats asthma' | publisher=BBC News | url=http://news.bbc.co.uk/1/hi/health/1632863.stm}}</ref> and peer-reviewed research to support this viewpoint. <!--
| |
| --><ref name="Jo Leonardi-Bee, David Pritchard, John Britton">{{cite journal |author=Leonardi-Bee J, Pritchard D, Britton J |title=Asthma and current intestinal parasite infection: systematic review and meta-analysis |journal=Am. J. Respir. Crit. Care Med. |volume=174 |issue=5 |pages=514-23 |year=2006 |pmid=16778161 |doi=10.1164/rccm.200603-331OC}}</ref>
| |
| | |
| [[Guaifenesin]], an expectorant available over the counter, may have a small effect in managing thickened bronchial mucus.
| |
| | |
| ==Prognosis==
| |
| The prognosis for asthmatics is good; especially for children with mild disease. For asthmatics diagnosed during childhood, 54% will no longer carry the diagnosis after a decade. The extent of permanent lung damage in asthmatics is unclear. Airway remodelling is observed, but it is unknown whether these represent harmful or beneficial changes.<ref name=Maddox /> Although conclusions from studies are mixed, most studies show that early treatment with glucocorticoids prevents or ameliorates decline in lung function as measured by several parameters.<ref name=beckett>Beckett PA, Howarth PH. Pharmacotherapy and airway remodelling in asthma? ''Thorax''. 2003;58(2):163-74. PMID 12554904</ref>
| |
| For those who continue to suffer from mild symptoms, corticosteroids can help most to live their lives with few disabilities. The mortality rate for asthma is low, with around 6000 deaths per year in a population of some 10 million patients in the United States.<ref name=McFadden />
| |
| Better control of the condition may help prevent some of these deaths.
| |
|
| |
|
| ==See also== | | ==See also== |
| Line 382: |
Line 52: |
| *[[Melatonin]] | | *[[Melatonin]] |
| *[[Occupational asthma]] | | *[[Occupational asthma]] |
|
| |
| == References ==
| |
| {{Reflist|2}}
| |
|
| |
| ==External links==
| |
| *[http://www.who.int/respiratory/asthma/en/ World Health Organization site on asthma]
| |
| *[http://www.who.int/mediacentre/factsheets/fs307/en/ World Health Organization fact sheet on asthma]
| |
| *[http://www.nhlbi.nih.gov/health/public/lung/index.htm#asthma National Heart, Lung, and Blood Institute — Asthma] – U.S. NHLBI Information for Patients and the Public page.
| |
| *[http://www.nhlbi.nih.gov/health/prof/lung/index.htm#asthma National Heart, Lung, and Blood Institute — Asthma] – U.S. NHLBI Information for Health Professionals page.
| |
| *[http://www.nlm.nih.gov/medlineplus/asthma.html MedLinePlus: Asthma] – a U.S. National Library of Medicine page.
| |
| *[http://www.aaaai.org American Academy of Allergy, Asthma, and Immunology] – a U.S. organization of medical professionals with a special interest in treating and researching conditions such as allergic rhinitis, asthma, atopic dermatitis/eczema, and anaphylaxis.
| |
| *[http://www.aafa.org Asthma and Allergy Foundation of America] – national nonprofit patient advocacy organization with information about asthma.
| |
| *[http://www.healthination.com/asthma.php Video: What is Asthma?]
| |
| *[http://www.asthma.org.uk Asthma UK] – a patient-oriented site with information on asthma and ways that UK residents can help improve asthma-related policy.
| |
| *[http://www.asthmaqld.org.au Asthma Foundation of Queensland] Information and education for Australian asthma sufferers.
| |
| *[http://www.asthmahelpline.com/ Asthma Helpline : Indian Non profit Asthma Patient Education website.]
| |
| *[http://www.atsdr.cdc.gov/HEC/CSEM/asthma/ Case Studies in Environmental Medicine (CSEM): Environmental Triggers of Asthma] – Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services.
| |
| *[http://www.asthma.ge/links.htm Asthma as Neurogenic Inflammatory Disease] Neurogenic aspects of asthma. Pathophysiological links with other inflammatory disorders.
| |
| *[http://tauac.typepad.com/ac/2007/03/tau_researchers.html Asthma and Socio-economic Status]
| |
| *[http://www.asthmacure.com India Asthma Care Society] Easy to understand asthma information site for patients.
| |
| *[http://www.segal.org/asthma/ The Segal Guide to Asthma] by Michael Segal MD PhD.
| |
| *[http://www.ourasthma.com Ourasthma.com] – a patient-oriented site with information on asthma inhalers.
| |
| * http://www.mismr.org/educational/asthma.html
| |
| * http://www.newtoasthma.com/
| |
|
| |
| {{Respiratory pathology}}
| |
| {{SIB}}
| |
|
| |
|
| [[Category:Asthma]] | | [[Category:Asthma]] |
| [[Category:Disease state]] | | [[Category:Disease]] |
| | [[Category:Pulmonology]] |
| [[Category:Emergency medicine]] | | [[Category:Emergency medicine]] |
| [[Category:Pulmonology]]
| |
| [[Category:Intensive care medicine]] | | [[Category:Intensive care medicine]] |
| [[Category:Mature chapter]] | | [[Category:Mature chapter]] |
| [[ar:ربو]]
| |
| [[zh-min-nan:He-ku]]
| |
| [[ca:Asma]]
| |
| [[cs:Astma]]
| |
| [[cy:Asthma]]
| |
| [[da:Astma]]
| |
| [[de:Asthma bronchiale]]
| |
| [[el:Άσθμα]]
| |
| [[et:Bronhiaalastma]]
| |
| [[es:Asma]]
| |
| [[eo:Astmo]]
| |
| [[eu:Asma]]
| |
| [[fr:Asthme]]
| |
| [[gl:Asma]]
| |
| [[ko:천식]]
| |
| [[hr:Astma]]
| |
| [[id:Asma]]
| |
| [[ia:Asthma]]
| |
| [[is:Astmi]]
| |
| [[it:Asma]]
| |
| [[he:אסתמה]]
| |
| [[lt:Astma]]
| |
| [[hu:Asztma]]
| |
| [[mk:Астма]]
| |
| [[nl:Astma]]
| |
| [[ja:気管支喘息]]
| |
| [[no:Astma]]
| |
| [[nn:Astma]]
| |
| [[pl:Astma oskrzelowa]]
| |
| [[pt:Asma]]
| |
| [[qu:Qharqayuy]]
| |
| [[ru:Бронхиальная астма]]
| |
| [[simple:Asthma]]
| |
| [[sk:Astma]]
| |
| [[sl:Astma]]
| |
| [[sr:Астма]]
| |
| [[su:Asma]]
| |
| [[fi:Astma]]
| |
| [[sv:Astma]]
| |
| [[vi:Bệnh suyễn]]
| |
| [[tr:Astım]]
| |
| [[uk:Астма]]
| |
| [[ur:دمہ]]
| |
| [[wa:Coûtresse d' alinne]]
| |
| [[zh:哮喘]]
| |
|
| |
|
| {{WikiDoc Help Menu}} | | {{WikiDoc Help Menu}} |
| {{WikiDoc Sources}} | | {{WikiDoc Sources}} |